[go: up one dir, main page]

Chow et al., 2002 - Google Patents

Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens

Chow et al., 2002

View PDF
Document ID
261887456218895640
Author
Chow Y
Wei O
Phogat
Sidorov I
Fouts T
Broder C
Dimitrov D
Publication year
Publication venue
Biochemistry

External Links

Snippet

The HIV-1 envelope glycoprotein (Env) undergoes conformational changes while driving entry. We hypothesized that some of the intermediate Env conformations could be represented in tethered constructs where gp120 and the ectodomain of gp41 are joined by …
Continue reading at scholar.archive.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Yang et al. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
Williams et al. Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies
Sundling et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site
Pauthner et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches
Parsons et al. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection
Arias et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity
Hioe et al. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
Dimitrov et al. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion
Gianvincenzo et al. Negatively charged glyconanoparticles modulate and stabilize the secondary structures of a gp120 V3 loop peptide: Toward fully synthetic HIV vaccine candidates
Dudkin et al. Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency
Madani et al. A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge
Chakrabarti et al. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies
Dimitrov et al. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation
Rosen et al. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization
Zhang et al. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4
Rashad et al. Macrocyclic envelope glycoprotein antagonists that irreversibly inactivate HIV-1 before host cell encounter
Phad et al. Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization
He et al. Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
Walker et al. High-throughput B cell epitope determination by next-generation sequencing
Meng et al. Design and biological evaluation of m-xylene Thioether-stapled short helical peptides targeting the HIV-1 gp41 Hexameric coiled–coil fusion complex
Bruxelle et al. HIV-1 entry and prospects for protecting against infection
Kaur et al. Exploring HIV vaccine progress in the pre-clinical and clinical setting: from history to future prospects
Cagigi et al. Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures
Chow et al. Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens
Saha et al. Designed cyclic permutants of HIV-1 gp120: implications for envelope trimer structure and immunogen design